S. aureus and IgE-mediated diseases: pilot or copilot? A narrative review

References

• Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339:520–532.
   PubMed Web of Science ®Google Scholar
• Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28:603–661.
   PubMed Web of Science ®Google Scholar
• Sollid JU, Furberg AS, Hanssen AM, et al. Staphylococcus aureus: determinants of human carriage. Infect Genet Evol. 2014;21:531–541.
   PubMed Web of Science ®Google Scholar
• Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis. 2005;5:751–762.
   PubMed Web of Science ®Google Scholar
• Verhoeven PO, Grattard F, Carricajo A, et al. An algorithm based on one or two nasal samples is accurate to identify persistent nasal carriers of Staphylococcus aureus. Clin Microbiol Infect. 2012;18:551–557.
   PubMedGoogle Scholar
• Nouwen JL, Ott A, Kluytmans-Vandenbergh MF, et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a “culture rule.” Clin Infect Dis. 2004;39:806–811.
   PubMedGoogle Scholar
• Nordengrun M, Michalik S, Volker U, et al. The quest for bacterial allergens. Int J Med Microbiol. 2018;308:738–750.
   PubMedGoogle Scholar
• Teufelberger AR, Broker BM, Krysko DV, et al. Staphylococcus aureus orchestrates type 2 airway diseases. Trends Mol Med. 2019;25(8):696–707.
   PubMedGoogle Scholar
• Tomassen P, Vandeplas G, Van Zele T, et al., Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 137(5): 1449–56 e4. 2016.
   PubMed Web of Science ®Google Scholar
• Van Zele T, Gevaert P, Watelet JB, et al. Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. J Allergy Clin Immunol. 2004;114:981–983.
   PubMed Web of Science ®Google Scholar
• Ertam I, Biyikli SE, Yazkan FA, et al. The frequency of nasal carriage in chronic urticaria patients. J Eur Acad Dermatol Venereol. 2007;21:777–780.
   PubMedGoogle Scholar
• Scadding GK. Allergens, germs and asthma. Clin Respir J. 2015;9:153–156.
   PubMedGoogle Scholar
• Lane AP, Truong-Tran QA, Schleimer RP. Altered expression of genes associated with innate immunity and inflammation in recalcitrant rhinosinusitis with polyps. Am J Rhinol. 2006;20:138–144.
   PubMedGoogle Scholar
• Ramanathan M Jr., Lee WK, Spannhake EW, et al. Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol. 2008;22:115–121.
   PubMedGoogle Scholar
• Suzaki H, Watanabe S, Pawankar R. Rhinosinusitis and asthma-microbiome and new perspectives. Curr Opin Allergy Clin Immunol. 2013;13:45–49.
   PubMedGoogle Scholar
• Van Bruaene N, Perez-Novo CA, Basinski TM, et al. T-cell regulation in chronic paranasal sinus disease. J Allergy Clin Immunol. 2008;121:1435–41, 41 e1–3.
   Google Scholar
• Derycke L, Perez-Novo C, Van Crombruggen K, et al. Staphylococcus aureus and chronic airway disease. World Allergy Organ J. 2010;3:223–228.
   PubMedGoogle Scholar
• Bachert C, Gevaert P, Holtappels G, et al. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107:607–614.
   PubMed Web of Science ®Google Scholar
• Flora M, Perrotta F, Nicolai A, et al. Staphylococcus Aureus in chronic airway diseases: an overview. Respir Med. 2019;155:66–71.
   PubMedGoogle Scholar
• Pinchuk IV, Beswick EJ, Reyes VE. Staphylococcal enterotoxins. Toxins (Basel). 2010;2:2177–2197.
   PubMed Web of Science ®Google Scholar
• Broker BM, Holtfreter S, Bekeredjian-Ding I. Immune control of Staphylococcus aureus - regulation and counter-regulation of the adaptive immune response. Int J Med Microbiol. 2014;304:204–214.
   PubMed Web of Science ®Google Scholar
• Krakauer T. Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions. Toxins (Basel). 2013;5:1629–1654.
   PubMedGoogle Scholar
• Chen JB, James LK, Davies AM, et al. Antibodies and super antibodies in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2017;139:1195–204 e11.
   PubMed Web of Science ®Google Scholar
• Flora M, Perna F, Abbadessa S, et al. Basophil activation test for Staphylococcus aureus enterotoxins in severe asthmatic patients. Clin Exp Allergy. 2021;51:536–545.
   PubMedGoogle Scholar
• Stentzel S, Teufelberger A, Nordengrun M, et al. Staphylococcal serine protease-like proteins are pacemakers of allergic airway reactions to Staphylococcus aureus. J Allergy Clin Immunol. 2017;139:492–500 e8.
   PubMed Web of Science ®Google Scholar
• Teufelberger AR, Nordengrun M, Braun H, et al. The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus-derived serine protease-like protein D. J Allergy Clin Immunol. 2018;141:549–59 e7.
   PubMed Web of Science ®Google Scholar
• Marone G, Rossi FW, Detoraki A, et al. Role of super allergens in allergic disorders. Chem Immunol Allergy. 2007;93:195–213.
   PubMedGoogle Scholar
• Marone G, Spadaro G, Liccardo B, et al. Superallergens: a new mechanism of immunologic activation of human basophils and mast cells. Inflamm Res. 2006;55 Suppl 1:S25–7.
   PubMedGoogle Scholar
• Kim YC, Won HK, Lee JW, et al. Staphylococcus aureus nasal colonization and asthma in adults: systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2019;7:606–15 e9.
   PubMed Web of Science ®Google Scholar
• Bachert C, Humbert M, Hanania NA, et al. Staphylococcus aureus and its IgE-inducing enterotoxins in asthma: current knowledge. Eur Respir J. 2020;55(4):1901592.
   PubMedGoogle Scholar
• Bachert C, van Steen K, Zhang N, et al. Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol. 2012;130:376–81 e8.
   PubMed Web of Science ®Google Scholar
• Song WJ, Jo EJ, Lee JW, et al. Staphylococcal enterotoxin specific IgE and asthma: a systematic review and meta-analysis. Asia Pac Allergy. 2013;3:120–126.
   PubMedGoogle Scholar
• Tomassen P, Jarvis D, Newson R, et al. Staphylococcus aureus enterotoxin-specific IgE is associated with asthma in the general population: a GA(2)LEN study. Allergy. 2013;68:1289–1297.
   PubMed Web of Science ®Google Scholar
• Sintobin I, Siroux V, Holtappels G, et al. Sensitisation to staphylococcal enterotoxins and asthma severity: a longitudinal study in the EGEA cohort. Eur Respir J. 2019;54(3):1900198.
   PubMedGoogle Scholar
• Song WJ, Chang YS, Lim MK, et al. Staphylococcal enterotoxin sensitization in a community-based population: a potential role in adult-onset asthma. Clin Exp Allergy. 2014;44:553–562.
   PubMed Web of Science ®Google Scholar
• Kowalski ML, Cieslak M, Perez-Novo CA, et al. Clinical and immunological determinants of severe/refractory asthma (SRA): association with Staphylococcal superantigen-specific IgE antibodies. Allergy. 2011;66:32–38.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Suzuki S, Ohta S, et al. Association between specific IgE to staphylococcus aureus enterotoxins A and B and asthma control. Ann Allergy Asthma Immunol. 2015;115:191–7 e2.
   PubMedGoogle Scholar
• Song WJ, Sintobin I, Sohn KH, et al. Staphylococcal enterotoxin IgE sensitization in late-onset severe eosinophilic asthma in the elderly. Clin Exp Allergy. 2016;46:411–421.
   PubMed Web of Science ®Google Scholar
• Bachert C, Gevaert P, Hellings P. Biotherapeutics in chronic rhinosinusitis with and without nasal polyps. J Allergy Clin Immunol Pract. 2017;5:1512–1516.
   PubMed Web of Science ®Google Scholar
• Bachert C, Zhang L, Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: focus on nasal polyposis. J Allergy Clin Immunol. 2015;136:1431–1440.
   PubMed Web of Science ®Google Scholar
• Sachse F, Becker K, von Eiff C, et al. Staphylococcus aureus invades the epithelium in nasal polyposis and induces IL-6 in nasal epithelial cells in vitro. Allergy. 2010;65:1430–1437.
   PubMed Web of Science ®Google Scholar
• Vickery TW, Ramakrishnan VR, Suh JD. The role of staphylococcus aureus in patients with chronic sinusitis and nasal polyposis. Curr Allergy Asthma Rep. 2019;19:21.
   PubMedGoogle Scholar
• Seiberling KA, Conley DB, Tripathi A, et al. Superantigens and chronic rhinosinusitis: detection of staphylococcal exotoxins in nasal polyps. Laryngoscope. 2005;115:1580–1585.
   PubMed Web of Science ®Google Scholar
• Cui XY, Miao JL, Lu HQ, et al. Serum levels of specific IgE to Staphylococcus aureus enterotoxins in patients with chronic rhinosinusitis. Exp Ther Med. 2015;9:1523–1527.
   PubMed Web of Science ®Google Scholar
• Cheng KJ, Wang SQ, Xu YY. Different roles of Staphylococcus aureus enterotoxin in different subtypes of nasal polyps. Exp Ther Med. 2017;13:321–326.
   PubMedGoogle Scholar
• Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138:1344–1353.
   PubMed Web of Science ®Google Scholar
• Cao PP, Zhang YN, Liao B, et al. Increased local IgE production induced by common aeroallergens and phenotypic alteration of mast cells in Chinese eosinophilic, but not non-eosinophilic, chronic rhinosinusitis with nasal polyps. Clin Exp Allergy. 2014;44:690–700.
   PubMedGoogle Scholar
• Martens K, Seys SF, Alpizar YA, et al. Staphylococcus aureus enterotoxin B disrupts nasal epithelial barrier integrity. Clin Exp Allergy. 2020;51:87–98.
   PubMedGoogle Scholar
• Rha MS, Kim SW, Chang DY, et al. Superantigen-related TH2 CD4(+) T cells in nonasthmatic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145:1378–88 e10.
   PubMedGoogle Scholar
• Ryu G, Kim DW. Th2 inflammatory responses in the development of nasal polyps and chronic rhinosinusitis. Curr Opin Allergy Clin Immunol. 2020;20:1–8.
   PubMedGoogle Scholar
• Kanemitsu Y, Fukumitsu K, Kurokawa R, et al. Moulds and Staphylococcus aureus enterotoxins are relevant allergens to affect Type 2 inflammation and clinical outcomes in chronic rhinosinusitis patients. ERJ Open Res. 2020;6(4):00265–2020.
   PubMedGoogle Scholar
• Dobretsov K, Negm H, Ralli M, et al. The theory of a “staphylococcus superantigen” in chronic rhinosinusitis with nasal polyps: myth or reality? Eur Rev Med Pharmacol Sci. 2019;23:48–54.
   PubMedGoogle Scholar
• Bachert C, Zhang N, Hellings PW, et al. Endotype-driven care pathways in patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2018;141(5):1543–1551.
   PubMed Web of Science ®Google Scholar
• Bachert C, Holtappels G, Merabishvili M, et al. Staphylococcus aureus controls interleukin-5 release in upper airway inflammation. J Proteomics. 2018;180:53–60.
   PubMedGoogle Scholar
• Hayes SM, Biggs TC, Goldie SP, et al. Staphylococcus aureus internalization in mast cells in nasal polyps: characterization of interactions and potential mechanisms. J Allergy Clin Immunol. 2020;145(1):147–159.
   PubMedGoogle Scholar
• Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:1–464.
   Web of Science ®Google Scholar
• Delemarre T, Holtappels G, De Ruyck N, et al. Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype. J Allergy Clin Immunol. 2020;146:337–43 e6.
   PubMed Web of Science ®Google Scholar
• Massoth L, Anderson C, McKinney KA. Asthma and chronic rhinosinusitis: diagnosis and medical management. Med Sci (Basel). 2019;7. DOI:https://doi.org/10.3390/medsci7040053
   Google Scholar
• Scott M, Small M, et al. Comorbidities, hypersensitivity and biomarkers in a real-world US nasal polyps population. Eur Respir J. 2019 Sep;54(suppl 63):PA5066.
   Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393–1414.
   PubMed Web of Science ®Google Scholar
• Bracken SJ, Abraham S, MacLeod AS. Autoimmune Theories of Chronic Spontaneous Urticaria. Front Immunol. 2019;10:627.
   PubMed Web of Science ®Google Scholar
• Kessel A, Helou W, Bamberger E, et al. Elevated serum total IgE–a potential marker for severe chronic urticaria. Int Arch Allergy Immunol. 2010;153:288–293.
   PubMed Web of Science ®Google Scholar
• Sharma AD. Role of nasal carriage of staphylococcus aureus in chronic urticaria. Indian J Dermatol. 2012;57:233–236.
   PubMedGoogle Scholar
• Ye YM, Hur GY, Park HJ, et al. Association of specific IgE to staphylococcal superantigens with the phenotype of chronic urticaria. J Korean Med Sci. 2008;23:845–851.
   PubMedGoogle Scholar
• Altrichter S, Hawro T, Liedtke M, et al. In chronic spontaneous urticaria, IgE against staphylococcal enterotoxins is common and functional. Allergy. 2018;73:1497–1504.
   PubMedGoogle Scholar
• Honda T, Nomura T, Kabashima K. Advances in atopic dermatitis and urticarial in 2016. J Allergy Clin Immunol. 2017;140:369–376.
   PubMed Web of Science ®Google Scholar
• Tauber M, Balica S, Hsu CY, et al. Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis. J Allergy Clin Immunol. 2016;137:1272–4 e3.
   PubMed Web of Science ®Google Scholar
• Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol. 1974;90:525–530.
   PubMed Web of Science ®Google Scholar
• Ong PY, Leung DY. The infectious aspects of atopic dermatitis. Immunol Allergy Clin North Am. 2010;30:309–321.
   PubMed Web of Science ®Google Scholar
• Williams RE, Gibson AG, Aitchison TC, et al. Assessment of a contact-plate sampling technique and subsequent quantitative bacterial studies in atopic dermatitis. Br J Dermatol. 1990;123:493–501.
   PubMed Web of Science ®Google Scholar
• Jinnestal CL, Belfrage E, Back O, et al. Skin barrier impairment correlates with cutaneous Staphylococcus aureus colonization and sensitization to skin-associated microbial antigens in adult patients with atopic dermatitis. Int J Dermatol. 2014;53:27–33.
   PubMed Web of Science ®Google Scholar
• Hwang J, Jaros J, Shi VY. Staphylococcus aureus in atopic dermatitis: past, present, and future. Dermatitis. 2020;31:247–258.
   PubMedGoogle Scholar
• Novosad J, Krcmova I. Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: where do we stand today? Int J Immunopathol Pharmacol. 2020;34:2058738420942386.
   Google Scholar
• Cheng SL. Immunologic pathophysiology and airway remodeling mechanism in severe asthma: focused on IgE-Mediated pathways. Diagnostics (Basel). 2021;11. doi:https://doi.org/10.3390/diagnostics12010011
   Google Scholar
• Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021;21(11):739–751.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Wong K, Millette LA, et al. The role of IgE in upper and lower airway disease: more than just allergy! Clin Rev Allergy Immunol. 2022;62(1):200–215.
   PubMedGoogle Scholar
• Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110–6 e1.
   PubMed Web of Science ®Google Scholar
• de Llano LP, Vennera Mdel C, Alvarez FJ, et al. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma. 2013;50(3):296–301.
   PubMed Web of Science ®Google Scholar
• Pillai P, Chan YC, Wu SY, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J. 2016;48:1593–1601.
   PubMed Web of Science ®Google Scholar
• Campo P, Soto Campos G, Moreira A, et al. Real-life study in non-atopic severe asthma patients achieving disease control by omalizumab treatment. Allergy. 2021;76(6):1868–1872.
   PubMed Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605.
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67–75.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Omalizumab. Summary of Product Characteristics. Accessed 25 February 2022. https://www.ema.europa.eu/en/documents/product-information/xolair-epar-product-information_en.pdf
   Google Scholar
• Jorde I, Hildebrand CB, Kershaw O, et al. Modulation of allergic sensitization and allergic inflammation by staphylococcus aureus enterotoxin B in an ovalbumin mouse model. Front Immunol. 2020;11:592186.
   PubMedGoogle Scholar
• Vu AT, Baba T, Chen X, et al. Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2–Toll-like receptor 6 pathway. J Allergy Clin Immunol. 2010;126(5):985–993.
   PubMedGoogle Scholar